MeiraGTx Holdings plc (MGTX)
After hours:
| Previous Close | 5.41 |
| Open | 5.42 |
| Bid | 5.22 x 100 |
| Ask | 5.30 x 300 |
| Day's Range | 5.25 - 5.45 |
| 52 Week Range | 3.49 - 8.35 |
| Volume | |
| Avg. Volume | 146,522 |
| Market Cap | 337.14M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.49 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
- GuruFocus.com
MeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023
Financial Summary: Cash Position Strengthens, Net Loss Narrows Year-Over-Year
ZacksMeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing - Company to present data from the Phase 1 AQUAx study in an oral presentation at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Completed dosing the three-arm randomized, sham-controlled Phase 1 clinical bridging study for AAV-GAD for the treatment of Parkinson’s disease - Co
